Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.
| Author | |
|---|---|
| Abstract |
:
Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, uptake. The aim of this study was to assess specific, target-mediated uptake in normal tissues, with immuno-PET in a phase I dose escalation study, using the anti-CD44 antibody RG7356 as example. |
| Year of Publication |
:
2018
|
| Journal |
:
EJNMMI research
|
| Volume |
:
8
|
| Issue |
:
1
|
| Number of Pages |
:
6
|
| Date Published |
:
2018
|
| URL |
:
https://dx.doi.org/10.1186/s13550-018-0358-8
|
| DOI |
:
10.1186/s13550-018-0358-8
|
| Short Title |
:
EJNMMI Res
|
| Download citation |
